<DOC>
	<DOCNO>NCT00860561</DOCNO>
	<brief_summary>This PMS aim assess efficacy , safety tolerability profile Faslodex everyday practice . Secondary objective PMS identify frequency serious adverse event unknown adverse event Faslodex .</brief_summary>
	<brief_title>Faslodex Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Postmenopausal woman Patients fail 2 prior hormone therapy ( The prior hormone therapy contain antiestrogen nonsteroidal Aromatase inhibitor ) Patients intolerant prior hormone therapy endocrine therapeutic option ( The prior hormone therapy contain antiestrogen nonsteroidal Aromatase inhibitor ) The patient receive Faslodex treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Efficacy profile</keyword>
	<keyword>Safety profile</keyword>
	<keyword>Faslodex</keyword>
</DOC>